Search results
Author(s):
Raman Dusaj
,
Jonathan S Reiner
Added:
3 years ago
The rapid development of percutaneous coronary and peripheral vascular interventional technologies, as well as non-invasive computed tomography (CT)-based imaging systems, has led to a dramatic increase in the number of patients receiving intravenous or intra-arterial contrast media (CM). It has been estimated that more than 80 million doses (8 million litres) of contrast material are…
View more
Author(s):
Marianne Brodmann
Added:
4 years ago
Prof Marianne Brodmann (Medical University of Graz, AT) discusses safety of pacilitaxel coated balloons.
Filmed on site by Radcliffe Cardiology.
Questions:
1.There have been safety concerns with paclitaxel DCB's. What is your take on this? (00:09)
2.Are you still implanting drug coated balloons? (02:16)
View more
Added:
3 years ago
Robert Rosenson (Mount Sinai, New York, US) discusses the safety and efficacy results of Evinacumab, an investigational fully-human monoclonal antibody that binds to and blocks the function of ANGPTL3, in patients with homozygous familial hypercholesterolemia (HoFH).
Questions:
1. What is the background of this trial?
2. What are the objectives of this trial?
3. What were the eligibility…
View more
Author(s):
Taiyeb M Khumri
,
Michael L Main
Added:
3 years ago
Ultrasound contrast agents capable of transpulmonary passage following intravenous injection have been commercially available since the 1990s. These agents are microbubbles, which are smaller than red blood cells and persist long enough (due to reduced rate of gas diffusion) to reach the left ventricle (LV).1–3 Ultrasound contrast agent applications included LV cavity opacification, enhancement…
View more
Author(s):
Peter J Fitzgerald
,
Martin B Leon
Added:
3 years ago
An unintended consequence of the market success of drug-eluting stents has been a growing concern about their safety and safety-related costs. These devices have been so quickly and widely adopted that their market penetration already equals that of some of the most popular pharmaceutical drugs. Consequently, the absolute significance of even a low incidence of side effects becomes magnified by…
View more
Author(s):
Steven E Nissen
Added:
6 years ago
This interview with Steven E. Nissen from Cleveland Clinic, Cleveland, US discusses Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION).
Filmed by Radcliffe Cardiology on-site at ESC 2017.
View more
Author(s):
Christie Ballantyne
Added:
1 year ago
ACC.23/WCC—We are joined by Dr Christie Ballantyne (Baylor College of Medicine, US) to discuss the results of a phase 2b clinical trial on the efficacy and safety of MK-0616, an oral macrocyclic PCSK9 inhibitor.In this trial sponsored by Merck Sharp & Dohme LLC, MK-0616 was compared to a placebo in over 380 participants with hypercholesterolemia, whose low-density lipoprotein cholesterol (LDL-C)…
View more
Author(s):
Peter J Fitzgerald
,
Martin B Leon
Added:
3 years ago
An unintended consequence of the market success of drug-eluting stents has been a growing concern about their safety and safety-related costs. These devices have been so quickly and widely adopted that their market penetration already equals that of some of the most popular pharmaceutical drugs. Consequently, the absolute significance of even a low incidence of side effects becomes magnified by…
View more
Author(s):
Michelle O'Donoghue
Added:
1 year ago
In this video, Dr Michelle L O’Donoghue summarises the long-term evaluation of evolocumab in the open label extension trial, FOURIER-OLE. The rationale of the study, the key results and how these add to the existing evidence will be discussed. This video will also highlight which patients would benefit the most from evolocumab, the safety profile in this extension study and take home-messages.
…
View more
Author(s):
Krzysztof Pujdak
,
Jan Kähler
,
Marc Werner
Added:
3 years ago
Significant stenosis of the left main (LM) coronary artery is observed in 7% of coronary angiographies.1 Coronary artery bypass grafting has traditionally been the treatment of choice. In recent years, percutaneous coronary intervention (PCI) has evolved as an alternative, especially for low and intermediate SYNTAX score patients.2 However, during PCI of bifurcation lesions, approximately 50% of…
View more